Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Glucagon-Like Peptide 1/therapeutic use"'
Publikováno v:
Revista Portuguesa de Farmacoterapia, Vol 8, Iss 2, Pp 28-38 (2016)
Introduction: Glucagon-like peptide analogues are a new class of drugs used in the treatment of type 2 diabetes mellitus that mimic the endogenous hormone glucagon-like peptide 1. Glucagon-like peptide 1 regulates glucose levels by stimulating glucos
Externí odkaz:
https://doaj.org/article/1cf6864fbfc6474c9a30a003eea6efc6
Autor:
Zheer Kejlberg Al-Mashhadi, Rikke Viggers, Rasmus Fuglsang-Nielsen, Peter Vestergaard, Søren Gregersen, Jakob Starup-Linde
Publikováno v:
Al-Mashhadi, Z K, Viggers, R, Fuglsang-Nielsen, R, Vestergaard, P, Gregersen, S & Starup-Linde, J 2022, ' The risk of major osteoporotic fractures with GLP-1 receptor agonists when compared to DPP-4 inhibitors : A Danish nationwide cohort study ', Frontiers in Endocrinology, vol. 13, 882998 . https://doi.org/10.3389/fendo.2022.882998
BackgroundType 2 diabetes mellitus (T2D) is associated with an increased fracture risk. There is little evidence for the effects of glucagon-like peptide 1 receptor agonists (GLP-1RA) on fracture risk in T2D. We aimed to investigate the risk of major
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cee8a9aed1565c4f9ae7864553eeca7b
https://vbn.aau.dk/ws/files/495957131/Al_Mashadi_et_al._2022_._The_risk_of_major_osteoporotic_fractures_with_GLP_1_receptor_agonists_when_compared_to_DPP_4_inhibitors_A_Danish_nationwide_cohort_study.pdf
https://vbn.aau.dk/ws/files/495957131/Al_Mashadi_et_al._2022_._The_risk_of_major_osteoporotic_fractures_with_GLP_1_receptor_agonists_when_compared_to_DPP_4_inhibitors_A_Danish_nationwide_cohort_study.pdf
Publikováno v:
Critical Care Clinics. 35:341-355
In health, postprandial glycemic excursions are attenuated via stimulation of insulin secretion, suppression of glucagon secretion, and slowing of gastric emptying. The incretin hormones, glucagon-like peptide-1 and glucose-dependent insulinotropic p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69d67bd99a3ec46d2b60cbf1f64be35a
https://doi.org/10.1016/j.ccc.2018.11.011
https://doi.org/10.1016/j.ccc.2018.11.011
Autor:
Kristina S. Boye, Mitch DeKoven, Hélène Sapin, Kirsi Norrbacka, Farhad Ali Khan, Victoria Divino
Publikováno v:
Diabetes Therapy
Introduction Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a relatively new class of injectable drugs used in the treatment of type 2 diabetes (T2D). This retrospective database study evaluated real-world treatment patterns of T2D patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4f6e2e5b8577561562ced9f8df95b7d
http://europepmc.org/articles/PMC5306123
http://europepmc.org/articles/PMC5306123
Publikováno v:
Revista Portuguesa de Farmacoterapia, Vol 8, Iss 2, Pp 28-38 (2016)
Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 8 No 2 (2016): Abril; 28-38
Revista Portuguesa de Farmacoterapia; v. 8 n. 2 (2016): Abril; 28-38
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Revista Portuguesa de Farmacoterapia / Portuguese Journal of Pharmacotherapy; Vol 8 No 2 (2016): Abril; 28-38
Revista Portuguesa de Farmacoterapia; v. 8 n. 2 (2016): Abril; 28-38
Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Introduction: Glucagon-like peptide analogues are a new class of drugs used in the treatment of type 2 diabetes mellitus that mimic the endogenous hormone glucagon-like peptide 1. Glucagon-like peptide 1 regulates glucose levels by stimulating glucos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::129500e3e0a096279694b4861ced11fa
http://revista.farmacoterapia.pt/index.php/rpf/article/view/116
http://revista.farmacoterapia.pt/index.php/rpf/article/view/116
Autor:
Roberta Sanguineti, Giorgio Luciano Viviani, Fabrizio Montecucco, François Mach, Franco Dallegri, Alessandra Puddu
Publikováno v:
Mediators of Inflammation; Vol 2013
Mediators of Inflammation
Mediators of Inflammation, Vol. 2013 (2013) P. 750540
Mediators of Inflammation, Vol 2013 (2013)
Mediators of Inflammation
Mediators of Inflammation, Vol. 2013 (2013) P. 750540
Mediators of Inflammation, Vol 2013 (2013)
The primary function of pancreatic beta cells is to produce and release insulin in response to increment in extracellular glucose concentrations thus maintaining glucose homeostasis. Deficient beta cell function can have profound metabolic consequenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f6854ff184c854ef513438142dccbb
https://doi.org/10.1155/2013/750540
https://doi.org/10.1155/2013/750540
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.